Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 724 of 6351
-
New cocktail of drugs aims to shrink Hard-to-Treat throat cancer
Disease control Recruiting nowThe goal of this study is to learn the efficacy and safety of nimotuzumab combined with toripalimab and gemcitabine/cisplatin regimen treatment recurrent/distant-metastasis nasopharyngeal carcinoma.
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 19:08 UTC
-
Can freezing nerves stop chronic migraine pain?
Symptom relief OngoingThe trial is a research study that tests a freezing technique called cryoneurolysis to see if it helps relieve pain in adults with chronic migraine. Chronic migraine is a condition that causes moderate to severe headache. In this study, the investigators want to evaluate the fre…
Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
New vacuum device aims to stop postpartum bleeding without surgery
Disease control CompletedThe purpose of this study is to evaluate the safety and effectiveness of the KOKO™ device in the control and reduction of primary abnormal postpartum uterine bleeding or hemorrhage.
Sponsor: KOKO Medical Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New heart valve implant offers hope for patients too sick for surgery
Disease control Recruiting nowProspective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System
Sponsor: TRiCares • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New triple therapy targets tough leukemia
Disease control Recruiting nowTo find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug aims to stop dangerous gut infection from returning
Prevention OngoingThis is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Phase 2/3 • Sponsor: Lumen Bioscience, Inc. • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
Sound waves zapping liver tumours without a scalpel
Disease control OngoingHistotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly e…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New bladder cancer drug shows promise in Late-Stage trial
Disease control OngoingThis Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Phase 3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a green tea compound prevent second heart attacks?
Disease control OngoingThe aim of this double-blind, randomized, placebo-controlled, multicenter study is to evaluate the pathogenetic effects of the dietary supplement "Tertinat" on a fundamental mechanism of atherosclerosis development: its ability to inhibit pathological desialylation of low-density…
Phase 2 • Sponsor: Institute for Atherosclerosis Research, Russia • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a family talk program shield teens from substance use?
Prevention OngoingRisk for substance use disorder (SUD) begins early in the life course. Although preventing and decreasing illicit and nonmedical drug use among youth is an urgent public health priority, there are currently few evidence-based prevention strategies feasible for delivery in the pri…
Sponsor: Brown University • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Could a 'Love Hormone' nasal spray help people with schizophrenia connect better?
Symptom relief OngoingResearch on schizophrenia spectrum disorders (SSD) patients with social impairment is essential for improving treatment, enhancing the lives of affected individuals, reducing stigma, and advancing our understanding of this complex psychiatric disorder. A clinical trial focusing o…
Phase 2 • Sponsor: Central Institute of Mental Health, Mannheim • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Triple drug cocktail targets Hard-to-Treat colorectal cancer
Disease control Recruiting nowTo learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a new pill tame HIV? early trial puts ACC017 to the test
Disease control CompletedACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase Ib/IIa, randomized, double-blind, parallel, dose ranging, placebo-controlled 'proof of concept' study is designed to evaluate the safety, tolerability, pharmacokinetics and anti…
Phase 1/2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug faces off against standard chemo
Disease control OngoingThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for ALS: first human trial of Gene-Targeting drug begins
Disease control Recruiting nowThis study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This …
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New combo therapy aims to boost remission in hodgkin lymphoma
Disease control Recruiting nowThe main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin …
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug may extend remission after CAR-T in myeloma
Disease control PausedThis phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment wi…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 05:00 UTC
-
Can community action stop violence against women? malawi trial aims to find out
Prevention Recruiting nowViolence against women is complex and must be addressed at multiple levels, with leadership from women themselves on how to bring about positive change to free women and girls from daily experiences of violence and to promote their rights. It is in this context that the Pamodzi K…
Sponsor: George Washington University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New hope for tough lung cancer: tarlatamab trial targets advanced disease
Disease control OngoingThe primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC